Do analysts believe MIRA Pharmaceuticals (USA Stocks:MIRA) will continue to rise?
 | By Raphi Shpitalnik | Macroaxis Story |
When it comes to playing the long game in the pharmaceutical industry, MIRA Pharmaceuticals is a stock that's worth a serious look. With a valuation market value of 3.04 and an analyst overall consensus rating of 'Strong Buy', this NASDAQ-listed company presents an intriguing investment opportunity.
MIRA's recent fiscal year-end results showed a net income loss of $12 million and an income tax expense of $8.5K. Although these figures may initially seem discouraging, it's important to remember that the pharmaceutical sector often requires significant upfront investment with the potential for high returns down the line. This is reflected in the analyst's highest estimated target price of 18.32, which indicates considerable upside potential.
The company's stock has shown high volatility, with a 52-week low of 0.51 and a high of 7.9799, a factor reflected in the coefficient of variation of 869.67 and downside deviation of 9.62. The high kurtosis and skewness values of 63.81 and 7.92 respectively also point to a high level of risk associated with this stock. However, the Sortino and Treynor ratios of 0.9222 and 1.16 suggest that the risk is balanced with potential rewards.
In summary, MIRA Pharmaceuticals may be a good choice for investors with a high risk tolerance and a long-term investment horizon. While the company's financial performance has been weak in the recent past, the strong analyst consensus indicates faith in the company's future prospects. Why have analysts adjusted their consensus from a firm buy or sell to a strong buy for MIRA Pharmaceuticals Common Stock? The stock is experiencing higher than average trading activity. Given the growing interest in the pharmaceutical sector, it's worthwhile to examine MIRA Pharmaceuticals in more depth. What can shareholders expect in August? Analysts' confidence in MIRA Pharmaceuticals has decreased compared to a month ago. However, the current recommendation from one analyst is a strong buy.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
MIRA Pharmaceuticals scores a 9 out of 100 in performance. The company's Beta (Market Risk) is 7.67, indicating a relatively high risk compared to the market. This suggests that MIRA Pharmaceuticals may outperform the market during positive trends but could underperform during downturns. To analyze future returns on MIRA Pharmaceuticals, consider its expected shortfall, day median price, and the correlation between potential upside and accumulation distribution.
Important Points
MIRA Pharmaceuticals, a player in the Drug Manufacturers - General industry, presents a compelling investment opportunity with a potential upside of 25.42%. Despite reporting a loss before tax of 12M, the company's strong Total Risk Alpha of 2.08 and positive Daily Balance of Power at 0.6126 indicate a promising future. However, investors should consider the high Mean Deviation of 20.76, which suggests potential volatility in the stock's performance.What is the right price you would pay to acquire a share of MIRA Pharmaceuticals,? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.
Watch out for price decline
Please consider monitoring MIRA Pharmaceuticals, on a daily basis if you are holding a position in it. MIRA Pharmaceuticals, is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as MIRA Pharmaceuticals, stock to be traded above the $1 level to remain listed. If MIRA Pharmaceuticals, stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
What is happening with MIRA Pharmaceuticals, Common this year
Annual and quarterly reports issued by MIRA Pharmaceuticals, Common are formal financial statements that are published yearly and quarterly and sent to MIRA stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as MIRA Pharmaceuticals, often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
MIRA Pharmaceuticals, Gross Profit
MIRA Pharmaceuticals, Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing MIRA Pharmaceuticals, previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show MIRA Pharmaceuticals, Gross Profit growth over the last 10 years. Please check MIRA Pharmaceuticals,'s gross profit and other fundamental indicators for more details.
A Deeper Perspective
Average experts consensus on MIRA Pharmaceuticals has changed. Currently, most analysts have less confidence in the entity as compared to a month ago. The current buy or sell recommendation of 0 analysts is Strong Buy.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of MIRA Pharmaceuticals, Common. Please refer to our Terms of Use for any information regarding our disclosure principles.